SCHEMBL2895893

SCHEMBL2895893

COc1ccc(CN2CC(O)C2)c(OC)c1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
TDP1 Q9NUW8 2/20 0.55
POLB P06746 2/20 0.55
KDM4E B2RXH2 5/20 0.54
MAPK1 P28482 2/20 0.54
TSHR P16473 2/20 0.54
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
APLNR P35414 1/20 0.53
MCHR1 Q99705 1/20 0.52
MAPT P10636 1/20 0.51
LMNA P02545 1/20 0.51
GAA P10253 1/20 0.51
TACR1 P25103 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19869696 0.84 TRPV6 (0.54) ALDH1A1TDP1KDM4ETSHRKMT2A
SCHEMBL18205140 0.82 KDM4E (0.52) ALDH1A1TDP1POLBKDM4EMAPK1
SCHEMBL9804694 0.82 KDM4E (0.61) ALDH1A1TDP1POLBKDM4EMAPK1
SCHEMBL6357988 0.81 KDM4E (0.53) ALDH1A1TDP1POLBKDM4EMAPK1
SCHEMBL2891323 0.81 KDM4E (0.49) ALDH1A1TDP1POLBKDM4EMAPK1
SCHEMBL2919640 0.80 MEN1 (0.56) ALDH1A1KDM4ETSHRKMT2AMEN1
SCHEMBL9831262 0.80 KDM4E (0.64) ALDH1A1TDP1POLBKDM4EMAPK1
SCHEMBL24778782 0.79 TSHR (0.52) ALDH1A1TDP1POLBKDM4EMAPK1
SCHEMBL28191688 0.78 KDM4E (0.63) ALDH1A1TDP1POLBKDM4EMAPK1
SCHEMBL30343566 0.78 MAPT (0.70) ALDH1A1TDP1POLBKDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010485-B1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2012-10-17 EP disclosed
EP-2010485-B1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2012-10-17 EP disclosed
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 US disclosed
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 US disclosed
US-20100286110-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2010-11-11 US disclosed
US-20100286110-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2010-11-11 US disclosed
US-20100286110-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2010-11-11 US disclosed
EP-2215078-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS Prosidion Limited (GB) 2010-08-11 EP disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
WO-2009050523-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 WO disclosed
WO-2009050522-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 WO disclosed
WO-2009050523-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 WO disclosed
EP-2010485-A1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS Prosidion Limited (GB) 2009-01-07 EP disclosed
WO-2007116230-A1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2007-10-18 WO disclosed
WO-2007116230-A1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists GPR119, GPR39, GIPR ALDH1A1 2266/4885TDP1 4635/4885POLB 4830/4885
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists GPR119, GIPR, GPR39 ALDH1A1 1721/4885TDP1 4740/4885POLB 4800/4885
US-20100286110-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS GPR119, GIPR, GPR39 ALDH1A1 1738/4885TDP1 4706/4885POLB 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.